4:02 PM
 | 
Apr 17, 2018
 |  BC Extra  |  Company News

Highmark, AstraZeneca in outcomes-based Symbicort contract

Blue Cross Blue Shield's Highmark Inc. affiliate and AstraZeneca plc (LSE:AZN; NYSE:AZN) entered into an outcomes-based contract for Symbicort budesonide/formoterol to treat symptoms in chronic obstructive pulmonary disease...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >